Parabolic Drugs Limited reported unaudited earnings results for the quarter ended September 30, 2018. For the quarter, the company reported total revenue from operations of INR 49.7 million against INR 239.6 million a year ago. Total income was INR 56.3 million against INR 243.0 million a year ago. Net loss after tax from continuing operations was INR 143.4 million against INR 142.3 million a year ago. Total comprehensive loss was INR 143.4 million against INR 142.3 million a year ago. Basic loss per share was INR 2.32 against INR 2.30 a year ago.